Scenarios 2027 / Scenarios
Rated at Standard Severe. Likelihood type: systemic. Source of scores: ginc-desk-v0.4. Upside scenario: impact levels measure the scale of change, not loss.
The sequence is uploaded from a provincial laboratory on a Sunday and matched against nothing known by Monday. The alert is not a press conference; it is an automated notice to forty manufacturing sites that a new construct is coming. The vaccine design takes six days. Trial sites that were kept warm for exactly this enrol their first volunteers in week three. Wastewater in eleven countries shows the pathogen by week five, which is how governments know where to send the first doses. Authorisation comes on day 94. By day 130 the plants in Dakar, Hyderabad, São Paulo and Kigali are filling vials, and the country that hoarded in 2021 finds it cannot corner a supply made on four continents. Hospitals in the first affected cities are stretched, not broken. Schools close for two weeks in three provinces and nowhere else. The economists who priced a pandemic at 3 per cent of world output revise to a few tenths. The failures are local and familiar. A country that left the surveillance network waits five months longer. Another has the doses and not the nurses. A third has both, and a public that learned in the last pandemic not to believe its health ministry.
The dateline is illustrative, not a forecast. The narrative is hypothetical; the historical anchors below are real events.
A novel pathogen emerges and the world's defences work. Genomic surveillance finds it within days, a platform vaccine is designed in a week and authorised within 100 days, and regional factories produce doses for every continent at once. Tests and antivirals arrive on the same schedule. The outbreak is held to an epidemic: no general lockdowns, borders open, schools open. The benefit goes to nations inside the surveillance and manufacturing network that can deliver doses and are believed when they ask people to take them. Nations outside it wait, as they did in 2021.
A shock most would count as progress. It is not upside for everyone: each record names who gains and who loses. Impact levels measure the scale of change, in either direction, and loads mark the capabilities a nation needs in order to capture the gain or absorb the loss.
| Event | Date | What happened | Calibrates |
|---|---|---|---|
| COVID-19 vaccines | 2020 | Vaccines were authorised about 11 months after the virus was sequenced | the baseline to beat |
| 100 Days Mission | 2021 | A plan, endorsed by the G7, to have vaccines, tests and treatments ready within 100 days of a pandemic threat being identified | Standard Severe target |
| WHO Pandemic Agreement | 20 May 2025 | Adopted by the World Health Assembly, covering surveillance, pathogen sharing and access to products | governance |
| mRNA technology transfer hub | 2021 onward | A hub in South Africa began sharing vaccine technology with manufacturers in low- and middle-income countries | regional manufacturing |
| Ebola ring vaccination | 2015–2019 | A vaccine trialled during the West African outbreak was used to contain later outbreaks in the Democratic Republic of the Congo | vaccine use in an outbreak |
| Mpox response in Africa | 2022–2024 | Vaccines reached affected African countries long after wealthy ones; an emergency was declared again in August 2024 | counter-anchor on access |
| Vaccine export restrictions | 2021 | Producers restricted exports and low-income countries waited months for doses | what regional manufacturing is meant to prevent |
Shown at their preset values. Parameters are not adjustable in this release and nothing on this page is computed from them. Custom settings run (Phase B) but are labelled 'non-standard run' and excluded from comparisons.
| Parameter | Default | Range or options | Note |
|---|---|---|---|
| Days from identification to authorised vaccine | 100 days | 60–200 | — |
| Nations in the surveillance network | 120 | 60–190 | — |
| Manufacturing regions with capacity | 5 | 2–6 | — |
| Share of world population reached in six months | 50 per cent | 20–80 | — |
| Public uptake | 70 per cent | 40–90 | — |
| Pathogen severity | COVID-like | options: milder / 1918-like | — |
High: capability band shifts expected under current plans. Medium: band shifts under 'none' policy response only. Low: strain without band shift. Loads are judgement-based until the Atlas connects. Domains link to the Atlas.
| Domain | Load | Channel |
|---|---|---|
| Hard | ||
| Defence and security | Low | logistics support; biosecurity |
| Strategic infrastructure | Medium | cold chain, laboratories and wastewater networks |
| Critical technology | High | genomic surveillance, vaccine platforms and regional manufacturing |
| Soft | ||
| Government effectiveness | High | public health command, regulation at speed, procurement |
| Human capital | High | health workforce and delivery to every district |
| Influence and cohesion | High | public trust and uptake; data sharing between states |
| Economic | ||
| Macro-financial | Medium | pre-agreed financing; avoided fiscal cost |
| Industry, trade and supply | Medium | supply chains for vials, lipids and reagents |
| Energy and resources | Low | no demand shock |
| Region | Exposure | Rationale |
|---|---|---|
| North America | High | Platform owners and manufacturers; trust deficits decide uptake |
| Europe | High | Manufacturing and regulation at speed |
| China | High | Large manufacturing base; data sharing is the question |
| Indo-Pacific | High | Strong surveillance and prior response capability |
| South Asia | High | India's manufacturing reaches the world; density at home |
| Gulf and Middle East | Medium | Capital to buy; a mobile workforce |
| Africa | High | New regional plants; delivery and workforce are the constraint |
| Latin America and Caribbean | Medium | Regional plants in Brazil and Argentina |
| Russia and Eurasia | Medium | Partly outside the sharing network |
| Indicator | Source | Threshold |
|---|---|---|
| Days from sequence to public sharing | GISAID | — |
| Vaccine manufacturing capacity by region | CEPI, WHO | — |
| Nations reporting wastewater surveillance | — | — |
| Standing trial networks and platform readiness exercises | — | — |
| Preparedness financing committed | Pandemic Fund | — |
| Vaccine confidence | national surveys | — |
| Ratification of the pandemic agreement | WHO | — |
From the GINC 250: trends rated Very high or Critical for this scenario. All S24 trend scores.
| Rating | Band or level | Why |
|---|---|---|
| Likelihood, two years | 3Possible | The pieces exist: platform vaccines, wastewater and genomic surveillance, regional manufacturing under construction and a pandemic agreement adopted in 2025. Whether they work together is untested, and the test needs an outbreak. |
| Likelihood, ten years | 4Likely | Estimates of a COVID-scale outbreak run near 2 per cent a year; the chance that the defence is ready when it comes rises with each year of investment. |
| Systemic impact | 4Major | Level 4 as a gain: the difference between a contained epidemic and a pandemic is several per cent of world output. |
| National impact | 4Major | Level 4: a nation inside the network keeps its hospitals, schools and borders open. |
| Confidence | low | The mechanism has never been run end to end. |
Source of scores: ginc-desk-v0.4. Confidence refers to the rating, not the scenario. Calibration sources are listed with the anchors above and on the methodology page.
Contested assumptions for the panel to resolve.
No signed commentary in this build.
0.4.0 · active0.4.0 · 3 October 2026 · Entered the Library at v0.4 as an upside scenario, with GINC desk scores.GINC (2027). Scenario S24 Hundred-day pandemic defence, Scenario Library v0.4. scenarios.ginc.org/library/hundred-day-pandemic-defenceContent and data are published under CC BY 4.0.